### 1 Early Prediction of In-Hospital Death of COVID-19 Patients: A Machine-Learning Model Based

# 2 on Age, Blood Analyses, and Chest X-Ray Score

- 3 Garrafa E.<sup>1,3§\*</sup>, Vezzoli M.<sup>1\*</sup>, Ravanelli M.<sup>2,4</sup>, Farina D.<sup>2,4</sup>, Borghesi A.<sup>2,4</sup>, Calza S.<sup>1</sup>, Maroldi R.<sup>2,4</sup>
- 4 <sup>1</sup>Department of Molecular and Translational Medicine, University of Brescia
- <sup>2</sup>Department of Medical and Surgical Specialties, Radiological Sciences and Public Health,
   University of Brescia
- 7 <sup>3</sup>ASST Spedali Civili di Brescia, Department of Laboratory
- 8 <sup>4</sup>ASST Spedali Civili di Brescia, Department of Radiology
- 9 <sup>§</sup>Corresponding autor
- 10 \*Authors contributed to the manuscript equally
- 11 Keywords: Analytes, COVID-19 Infectious Disease, Random Forests, SMOTE, VIM, PDP
- 12 Abstract

Background: To develop and validate an early-warning model to predict in-hospital mortality on
admission of COVID-19 patients at an emergency department (ED).

Methods: In total, 2782 patients were enrolled between March 2020 and December 2020, including 2106 patients (first wave) and 676 patients (second wave) in the COVID-19 outbreak in Italy. The first-wave patients were divided into two groups with 1474 patients used to train the model, and 632 to validate it. The 676 patients in the second wave were used to test the model. Age, 17 blood analytes and Brescia chest X-ray score were the variables processed using a Random Forests classification algorithm to build and validate the model. ROC analysis was used to assess the model performances. A web-based deathrisk calculator was implemented and integrated within the Laboratory Information System of the hospital.

Results: The final score was constructed by age (the most powerful predictor), blood analytes (the strongest predictors were lactate dehydrogenase, D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, Lymphocyte %, Ferritin std and Monocyte %), and Brescia chest X-ray score. The areas under the receiver operating characteristic curve obtained for the three groups (training, validating and testing) were 0.98, 0.83 and 0.78, respectively.

- 27 Conclusions: The model predicts in-hospital mortality on the basis of data that can be obtained in a short
- time, directly at the ED on admission. It functions as a web-based calculator, providing a risk score which
- is easy to interpret. It can be used in the triage process to support the decision on patient allocation.

30

#### 31 Introduction

Starting from late February 2020, the COVID-19 outbreak struck the north of Italy causing more than 30,000 deaths in Lombardy alone, up to the end of March 2021. At the beginning of the outbreak, the Spedali Civili di Brescia (SCBH), the university hospital of one of the hardest hit cities in Europe, was faced with a 'flash flood' of severely ill patients seeking admission to the Emergency Department (ED). For several weeks, their number exceeded the available resources, obliging a continuous organizational restructuring of the hospital wards (Garrafa et al., 2020b).

In those weeks, given the limited evidence of clinically proven predictors (Marengoni et al., 2021)(Wynants et al., 2020)(Sperrin et al., 2020), prioritizing hospital admission of non-critical patients was an arduous task. Essentially, the criteria were based on the presence of fever, respiratory symptoms and the level of blood oxygenation. A significant drawback of this approach was that patients referring to the ED with very similar clinical findings underwent inconsistent assessments. In this scenario, the availability of predictors would have been extremely beneficial, not only to triage patients, but also to

44 monitor hospitalized patients and warn of exacerbation of the outbreaks.

45 Starting from March 2020, all patients referred to EDs underwent a chest X-ray at admission or within a 46 few hours. With the purpose of grading pulmonary involvement and tracking changes objectively over 47 time, a chest X-ray severity score was developed (Brescia X-ray score) (Borghesi and Maroldi, 48 2020)(Maroldi et al., 2020)(Borghesi et al., 2020a)(Borghesi et al., 2020b). The score was able to predict 49 in-hospital mortality in 302 patients. In addition to the chest X-ray severity score, a dedicated blood 50 sampling profile was included in the COVID-19 ED work-up (Garrafa et al., 2020a). Among its 17 blood 51 analytes, the sampling profile encompassed hemachrome, inflammation biomarkers such as C reactive 52 protein (CRP), lactate dehydrogenase (LDH) and Ferritin, and coagulation markers (Fibrinogen and D-53 dimer). Since that time, the medical literature began to encompass an increasing number of studies 54 advocating the prognostic value of single or grouped blood parameters (Bonetti et al., 2020)(Borghi et 55 al., 2020)(Avouac et al., 2021). All of these parameters were present in our COVID-19 sampling profile.

This study aims to develop and validate an Early-Warning Model (BS-EWM), predictive of in-hospital death, based on data that could easily be acquired on admission to the ED: age, simple blood biomarkers and chest X-ray. The model was constructed based on the analysis of a cohort of 2872 COVID-19 patients treated in a single reference center over a 10-month period.

This paper adheres to the TRIPOD checklist for predictive model development and validation (Collinset al., 2015).

62 The study was approved by the local ethics committee (NP 4000).

#### 63 Materials and Methods

The dataset contained 2782 COVID-19 symptomatic patients, hospitalized between March and 64 65 December 2020 at SCBH after referring to the ED. In all patients, the following variables were retrieved from the SCBH database: age, sex, length of hospitalization, Brescia X-ray score (Borghesi and Maroldi, 66 67 2020), Alive/Dead, and 17 blood analytes acquired at admission (D-dimer, Fibrinogen, lactate dehydrogenase (LDH), Neutrophils, Lymphocytes, Neutrophil/Lymphocyte ratio (NLR), Lymphocytes 68 69 %, Neutrophils %, C-reactive protein (CRP), white blood cell (WBC) count, Basophils, Basophils %, 70 Eosinophils, Eosinophils %, Monocytes, Monocytes %, standardized Ferritin). Blood tests were acquired 71 within 24 hours after admission to the hospital.

According to the two temporal peaks of incidence of the COVID-19 outbreak in Lombardy, the 2782 patients were divided into two groups: (*i*) March–April (MA) including 2106 patients admitted during the first wave; (*ii*) May–December (MD) including 676 patients in the second wave. Quantitative variables were described using Mean (SD), Median (IQR) and Range (min–max), while categorical variables were reported as counts and percentages. The comparisons between groups were performed using the Wilcoxon rank-sum test for quantitative variables and Fisher's exact test for qualitative variables.

The relationships between the 17 analytes and the Brescia X-ray score were inspected using the Spearman correlation coefficient,  $\rho_s$ , and visualizing results using a correlation plot (Dancelli et al., 2013)(Marziano et al., 2019) (Figure S1).

To estimate the BS-EWM, the outcome (Alive/Dead) was modeled using as covariates: (*i*) Brescia X-ray score, (*ii*) 17 analytes, (*iii*) age. Since most of the covariates analyzed were strongly correlated (multicollinearity) (Figure S1) and their relationships with the outcome were non-linear, the BS-EWM was estimated using Random Forests (Breiman, 2001)(Carpita and Vezzoli, 2012), a non-parametric machine-learning method (Vezzoli, 2011)(Vezzoli et al., 2017). Moreover, the algorithm is able to

manage missing values which are common in clinical studies. The "on-the-fly-imputation" algorithm
(Hong and Lynn, 2020) imputes data when it grows the forest handling interactions and non-linearity in
the dataset.

Since the prevalence rate of death in the two waves was different (20% in MA vs 12% in MD), a strategy

91 to generalize results in unbalanced datasets was applied, adopting a rebalancing method able to improve

92 the detection of patients with a high death-risk.

93 The EWM was developed using the 2106 patients in the first COVID-19 wave (MA 2020) when in-94 hospital death prevalence was 20%. Seventy percent of them (1474 patients) were used for training the 95 model and the remainder (632 patients) for testing it. Patients were randomly assigned to the two 96 subgroups, and further stratified according to the outcome (Alive/Dead). Consequently, both the training 97 and testing subgroups included the same rate of deaths (20.09%) as the full sample (2106 patients). With 98 such a "moderate" incidence of death, the dataset was statistically unbalanced. This limitation could have 99 implied the development of a model yielding unsatisfactory results in predicting new observations for 100 the minority class, i.e., patients with death as outcome. An approach to address this limitation is to 101 oversample the minority class (deceased patients) and, subsequently, create the predictive model (BS-102 EWM). The Synthetic Minority Oversampling Technique (SMOTE) (Chawla et al., 2002) was chosen. 103 The SMOTE function oversamples the minority class by using bootstrapping and k-nearest neighbor to 104 synthetically create additional observations belonging to that class (Dead). The procedure is combined 105 with under-sampling of the majority class (Alive). To determine the optimum number of k-groups into 106 which to assign the dataset, a matrix containing the 17 analytes and the Brescia X-ray score was used to 107 compute the hierarchical cluster analysis (Salvi et al., 2019)(Codenotti et al., 2016). By means of 108 silhouette analysis, k=2 was determined as the optimal number of clusters into which to assign the dataset. 109 Hence, a synthetic rebalanced dataset was obtained with an equal number of Living and Deceased 110 patients (888+888). The rebalancing procedure enabled a risk score to be devised ranging from 0 to 1 111 with a threshold of 0.5 to separate non-severely affected from severely affected patients. Subsequently, 112 the model was tested on the subgroup of 632 patients in the first wave excluding the training set. A further 113 validation of the EWM was conducted on the 676 COVID-19 patients in the second wave (MD 2020).

114 The Relative Variable Importance Measure (rel VIM)(Carpita and Vezzoli, 2012) (Doglietto et al.,

115 2020b) and the Partial Dependence Plots (PDP) (Friedman, 2001)(Doglietto et al., 2020a) were extracted

116 from the model for a better understanding of the relationship between outcome and covariates.

117 The predictions extracted from the Random Forests classification were interpreted as in-hospital death

- 118 probability conditional on the combination of the values of analytes, Brescia X-ray score and age in
  110 COVID 10 patients at admission to the ED
- 119 COVID-19 patients at admission to the ED.

120 The BS-EWM performance was evaluated by Area Under the Curve (AUC) of a Receiver Operating

121 Characteristic (ROC) curve. The robustness of the model was compared to other models by running

122 Gradient Boosting Machine (GBM, a machine-learning approach and competitor to Random Forests),

- 123 and Logistic Regression, and computing the same metrics.
- 124 The BS-EWM score is available for use online (https://bdbiomed.shinyapps.io/covid19score). In the
- 125 SCBH it is integrated within LIS (Laboratory Information System) returning the death-risk score directly
- 126 from the medical report.

### 127 Results

### 128 **Description of the sample**

The entire sample analyzed in this paper contained 2782 COVID-19 patients (1010 female (36.3%) and
1772 male (63.7%)), admitted to the ED and hospitalized at SCBH from March to December 2020.
During these 10 months, the pandemic had two temporal waves: March–April (2106 patients, 75.70% of
the entire sample) and May–December (676 patients, 24.30% of the entire sample) (Table S1). The model

133 was trained on a subsample extracted from the first wave (70%) and tested (*i*) on data not used to calibrate

the model (remaining 30% from the first wave) and (*ii*) on data from the second wave.

- 135 The first-wave subsample contained 2106 COVID-19 patients hospitalized in March-April 2020 at
- 136 SCBH: 744 females (35.3%), and 1362 males (64.7%) (Table 1). During that period, 423 patients died

137 (20.09% of the total): 131 females (31%) and 292 males (69%). Their mean age±SD was 66.89±14.19:

138  $67.93\pm15.40$  for females and  $66.32\pm13.45$  for males (p-value=0.001). The mean age of deceased patients

- 139 was 76.21 $\pm$ 9.12, while for living patients, it was 64.55 $\pm$ 14.27 (p-value < 0.001). Mean hospital stay was
- 140 13.58±11.58 days (from a minimum of 0 to a maximum of 140 days): 11.33±10.98 days for patients who
- 141 died,  $14.15\pm11.66$  days for surviving patients (p-value < 0.001).

The second-wave subsample contained 676 COVID-19 patients hospitalized in May–December 2020 at SCBH: 266 females (39.3%), 410 males (60.7%) (Table 1). During the 8 months of the second wave, 82 patients died (12.13%): 26 females (31.7%) and 56 males (68.3%). The mean age of deceased patients was 76.72 $\pm$ 10.79 versus 65.30 $\pm$ 15.20 for surviving patients (p-value < 0.001). The mean hospital stay was 15.35 $\pm$ 11.58 days (from a minimum of 0 to a maximum 79 days): 17.77 $\pm$ 10.75 days for patients who died, 14.95  $\pm$ 11.67 days for surviving patients (p-value=0.008).

148 The descriptive statistics for all variables in the dataset are presented in Table S2 and were computed and 149 stratified by the two waves (MA vs MD) and by outcome (Alive vs Dead). The two subsets were similar 150 for most variables.

151 The correlations between the 17 analytes and the Brescia X-ray score were investigated using Spearman 152 correlation coefficients and visualized using a correlation plot (Figure S1). The Brescia X-ray score was 153 positively correlated with Neutrophil to Lymphocyte ratio, CRP, LDH, standardized Ferritin, and D-154 Dimer, and was negatively correlated with Lymphocyte %, Monocyte %, and Basophil %.

#### 155 **BS-EWM**

A machine-learning model (BS-EWM) was developed by inputting a dataset of 2782 COVID-19 patients admitted to the ED and hospitalized at SCBH from March to December 2020. The majority of patients (2106/2782, 75.70%) belonged to the first wave (MA), the remaining fraction (676/2782, 24.30%) to the second wave (MD). As outcome, the machine-learning model had the condition Dead/Alive, and, as covariates: age, Brescia X-ray score and 17 blood sample analytes.

Figure 1 reports the flow chart that describes how data were divided for training, validation and testingthe BS-EWM.

163 The SMOTE procedure, rebalancing the Dead/Alive ratio (50% vs. 50%) from the original 20.09%,

164 improved accuracy, specificity, and sensitivity of the Random Forest applied on it (see Table S3 which

165 compares performance metrics with/without the SMOTE method).

166 The rel VIM and PDP were extracted from the Random Forests (Figure 2, panel A and B respectively).

167 In panel A1, the rel VIM of BS-EWM based on age, Brescia X-ray score and 17 blood analytes are

168 reported on a bar plot. Since age was strongly associated with the risk of death, it masked the role of the

169 other covariates. For completeness, the relevance of the 17 analytes and Brescia X-ray score was 170 estimated in an additional EWM, in which the covariate 'age' was excluded. In the resulting bar plot 171 (Figure 2, panel A2), 9/17 analytes and the Brescia X-ray score were noted as being important in 172 predicting the risk of death (rel VIM>60). The effects of changes in covariate values on the risk of death-173 threshold of the EWM were reported by means of a PDP (a 2D plot in the x-y plane) (Figure 2, panel 174 B). Only Fibrinogen was excluded from this graphical representation since in Table 1, it was not 175 significantly different in the two subpopulations Deceased/Alive. Most PDPs showed nonmonotonic 176 increasing relationships between the x-variable and the EWM, resulting in a plateau corresponding to 177 high values of *x*.

When compared to other models such as GBM and Logistic Regression, the Random Forest showed better performance in terms of AUC, sensitivity, and specificity. The in-sample sensitivity (0.93) yielded by the model was the highest, and it maintained an important 0.82 in validating the out-of-sample sensitivity, and this decreased to 0.73 when testing the MD subgroup (see Table 2 which contains details on all the metrics extracted from the ROC analysis). ROC curves are visualized in Figure 3 where, for each model (Random Forest, GBM and Logistic Regression), the performances in Training, Validating and Testing are compared in a unique graph.

### 185 **Discussion**

186 The dataset for the development, validation and testing of the BS-EWM originated entirely from an 187 Italian region, potentially limiting the generalizability of the risk score in other areas of the world. 188 Additional validation studies from different geographic areas are welcomed. Furthermore, though the 189 BS-EWM has been validated using blood sample values obtained by instruments that satisfy internal and 190 external quality control, different equipment could lead to divergent results (Martens et al., 2021)(Lippi 191 et al., 2020). Therefore, it would be appropriate to harmonize the results. Another limit could have been 192 the presence of missing values, though the BS-EWM has also performed adequately in this condition 193 since it used a multiple imputation technique to overcome the problem. Finally, it is important to point 194 out that the BS-EWM risk score should not be used for asymptomatic COVID-19 patients or for the 195 pediatric population.

Though the BS-EWM has been developed on a cohort of 2106 patients belonging to the COVID-19 first wave, the model also demonstrated a sensitivity greater than 70% in the early prediction of high risk in patients in the second wave, when in-hospital mortality was 40% lower.

Several predictive models have recently been applied to COVID-19 cohorts with variable results, some of them previously developed to predict mortality for community-acquired pneumonia, such as the Pneumonia Severity Index, CURB-65, qSOFA, and MuLBSTA(Yavuz et al., 2021)(Lazar Neto et al., 2021)(Artero et al., 2021), NEWS2 criteria (Myrstad et al., 2020)(Gidari et al., 2020), and SCAP score (Anurag and Preetam, n.d.). Novel early-warning scores have been specifically built on COVID-19 patient series using different techniques such as parametric and non-parametric tests (Linssen et al., 2020) or artificial intelligence techniques such as the COVID-GRAM score (Liang et al., 2020).

While these models are mostly based on age and a set of vital (clinical) parameters, in addition to age, the BS-EWM depends on blood parameters. It is conceivable that blood analytes capture a snapshot at hospital admission signaling a specific bodily reaction to viral infection in terms of hyperinflammation, immune response and thrombophilia. On the other hand, the other models are more influenced by the general status of the patient, which may be determined by concomitant and pre-existing diseases.

211 According to the International Federation of Clinical Chemistry (Bohn et al., 2020), no single 212 biochemical or hematological marker is sufficiently sensitive or specific to predict the outcome of SARS-213 CoV-2 infection. Notably, the IFCC recommends that the interpretation of laboratory abnormalities 214 should be based on groups of analytes (Bohn et al., 2020). In the BS-EWM, three analytes reached a 215 significant value in predicting death: LDH, D-dimer and NLR. LDH is a non-specific indicator of tissue 216 damage (Bohn et al., 2020)(Liang et al., 2020) that emerges as one of the most consistently elevated 217 markers in patients at higher risk of developing adverse outcomes, probably because COVID-19 infection 218 is characterized by systemic tissue damage. Another key feature of SARS-CoV-2 is the coagulopathy: 219 high levels of D-dimers have been reported to correlate with unfavorable disease progression in several 220 cohorts of patients. The coagulopathy linked to COVID-19 infection is likely to involve a complex 221 interplay between pro-thrombotic and inflammatory factors, thus the combined analysis of both 222 inflammatory and thrombophilic markers could play an important role in the early identification of 223 patients at higher risk of unfavorable progression (Bohn et al., 2020)(Lazzaroni et al., 2021). Finally, 224 lymphopenia has become a hallmark of SARS-CoV-2. It has been demonstrated in almost all 225 symptomatic patients, though in varying degrees. Disease severity has been correlated with the level of

lymphocyte count reduction. A direct infection of lymphocytes, which express the coronavirus receptor ACE-2, is among the mechanisms proposed. A poor prognosis is also associated with an elevated neutrophil count combined with lymphopenia, resulting in a high NLR. The increase in granulocytes is the result of the cytokine storm induced by the virus and is responsible for tissue damage (Bonetti et al., 2020)(Bohn et al., 2020).

A further remark concerning the blood analytes is that, in the BS-EWM, the thresholds of the single analytes exceeding the 0.5 death-risk closely overlap with the values recently proposed by other authors (Webb et al., 2020)(Caricchio et al., 2021) (Figure 2, panel B).

234 The present study is not unique in encompassing radiological findings combined with blood analysis. 235 The study by Schalekamp et al. (Schalekamp et al., 2020) integrated blood analysis parameters and 236 radiological information derived by grading chest X-rays (0-8 scale points). Unlike the cited study, with 237 the BS-EWM in this study, the radiological score did not reach a high relevance (rel VIM) in predicting 238 high risk. This difference can be explained by the different approaches used to build the model (Logistic 239 regression vs Random Forests) and by the high degree of correlation of the X-ray score with multiple 240 blood analytes: "collinearity" thus could have "stolen" importance from the information provided by 241 imaging. Nevertheless, at admission, the chest X-ray score of patients who subsequently died was 242 significantly higher than for patients who survived. Furthermore, the chest X-ray score may provide 243 additional stability to the model, playing an important role in the case of missing data in the blood sample 244 counterpart.

An important and pragmatic aspect offered by the BS-EWM is that the biomarkers employed may be obtained by the emergency laboratory in less than an hour (Garrafa et al., 2020a) and, differently from other biomarkers (Kyriazopoulou et al., 2021, p. 19), they are non-expensive and frequently used also in developing countries. It is important to note that the same methodology could be applied to other infections and be practical to triage people.

Most laboratories, including the small or peripheral ones, may provide results in a short time. At the Spedali Civili of Brescia, the BS-EWM is integrated within the Laboratory Information System. It works as a web-based calculator and is easy to interpret. It provides a risk threshold of 0.5, above which patients are graded as having a potentially high death-risk, thus supporting closer clinical observation or

admission to a high-intensive care ward. In patients yielding a low risk (score 0 to 0.49), the decision by
 clinicians to allocate them to a low-intensive care ward or to monitoring is further sustained.

Finally, the need to regularly update models and closely monitor their performances over time and geographically should be underlined, given the rapidly changing nature of the disease and its

258 management.

#### 259 References

- Anurag A, Preetam M. n.d. Validation of PSI/PORT, CURB-65 and SCAP scoring system in COVID 19 pneumonia for prediction of disease severity and 14-day mortality. *Clin Respir J* n/a.
   doi:https://doi.org/10.1111/crj.13326
- 263 Artero A, Madrazo M, Fernández-Garcés M, Muiño Miguez A, González García A, Crestelo Vieitez A, 264 García Guijarro E, Fonseca Aizpuru EM, García Gómez M, Areses Manrique M, Martinez 265 Cilleros C, Fidalgo Moreno MDP, Loureiro Amigo J, Gil Sánchez R, Rabadán Pejenaute E, 266 Abella Vázquez L, Cañizares Navarro R, Solís Marquínez MN, Carrasco Sánchez FJ, González Moraleja J, Montero Rivas L, Escobar Sevilla J, Martín Escalante MD, Gómez-Huelgas R, 267 268 Ramos-Rincón JM, SEMI-COVID-19 Network. 2021. Severity Scores in COVID-19 Pneumonia: 269 a Multicenter, Retrospective, Cohort Study. J Gen Intern Med. doi:10.1007/s11606-021-06626-270 7
- Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, Mahou SE, Pertuiset E, Pham T, Marotte
  H, Servettaz A, Domont F, Chazerain P, Devaux M, Claudepierre P, Langlois V, Mekinian A,
  Maria ATJ, Banneville B, Fautrel B, Pouchot J, Thomas T, Flipo R-M, Richez C. 2021. COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with
  rituximab: a cohort study. *Lancet Rheumatol* 0. doi:10.1016/S2665-9913(21)00059-X
- Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, Wang C-B, Mancini N, Steele S, Adeli K.
  2020. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC
  taskforce evaluation of the latest evidence. *Clin Chem Lab Med* 58:1037–1052.
  doi:10.1515/cclm-2020-0722
- Bonetti G, Manelli F, Patroni A, Bettinardi A, Borrelli G, Fiordalisi G, Marino A, Menolfi A, Saggini S,
  Volpi R, Anesi A, Lippi G. 2020. Laboratory predictors of death from coronavirus disease 2019
  (COVID-19) in the area of Valcamonica, Italy. *Clin Chem Lab Med CCLM* 58:1100–1105.
  doi:10.1515/cclm-2020-0459
- Borghesi A, Maroldi R. 2020. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for
   quantifying and monitoring disease progression. *Radiol Med (Torino)* 125:509–513.
   doi:10.1007/s11547-020-01200-3
- Borghesi A, Zigliani A, Golemi S, Carapella N, Maculotti P, Farina D, Maroldi R. 2020a. Chest X-ray
  severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302
  patients from Italy. *Int J Infect Dis* 96:291–293. doi:10.1016/j.ijid.2020.05.021
- Borghesi A, Zigliani A, Masciullo R, Golemi S, Maculotti P, Farina D, Maroldi R. 2020b. Radiographic
   severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. *Radiol Med (Torino)* 1–4. doi:10.1007/s11547-020-01202-1
- Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, Grossi C, Blengino S, Tincani A,
  Franceschini F, Andreoli L, Lazzaroni MG, Piantoni S, Masneri S, Crisafulli F, Brugnoni D,
  Muiesan ML, Salvetti M, Parati G, Torresani E, Mahler M, Heilbron F, Pregnolato F, Pengo M,

Tedesco F, Pozzi N, Meroni PL. 2020. Anti-Phospholipid Antibodies in COVID-19 Are Different
 From Those Detectable in the Anti-Phospholipid Syndrome. *Front Immunol* 11.
 doi:10.3389/fimmu.2020.584241

- 299 Breiman L. 2001. Random Forests. *Mach Learn* **45**:5–32. doi:10.1023/A:1010933404324
- Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S, Fleece D, Bromberg M, Criner GJ. 2021.
   Preliminary predictive criteria for COVID-19 cytokine storm. *Ann Rheum Dis* 80:88–95.
   doi:10.1136/annrheumdis-2020-218323
- Carpita M, Vezzoli M. 2012. Statistical evidence of the subjective work quality: the fairness drivers of
   the job satisfaction. *Electron J Appl Stat Anal* 5:89–107. doi:10.1285/i20705948v5n1p89
- Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. 2002. SMOTE: Synthetic Minority Over-sampling
   Technique. *J Artif Intell Res* 16:321–357. doi:10.1613/jair.953
- Codenotti S, Vezzoli M, Poliani PL, Cominelli M, Bono F, Kabbout H, Faggi F, Chiarelli N, Colombi
  M, Zanella I, Biasiotto G, Montanelli A, Caimi L, Monti E, Fanzani A. 2016. Caveolin-1,
  Caveolin-2 and Cavin-1 are strong predictors of adipogenic differentiation in human tumors and
  cell lines of liposarcoma. *Eur J Cell Biol* 95:252–264. doi:10.1016/j.ejcb.2016.04.005
- Collins GS, Reitsma JB, Altman DG, Moons KGM. 2015. Transparent reporting of a multivariable
   prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ* 350:g7594. doi:10.1136/bmj.g7594
- Dancelli L, Manisera M, Vezzoli M. 2013. On Two Classes of Weighted Rank Correlation Measures
   Deriving from the Spearman's ρ In: Giudici P, Ingrassia S, Vichi M, editors. Statistical Models
   for Data Analysis, Studies in Classification, Data Analysis, and Knowledge Organization.
   Heidelberg: Springer International Publishing. pp. 107–114. doi:10.1007/978-3-319-00032-9\_13
- Doglietto F, Vezzoli M, Biroli A, Saraceno G, Zanin L, Pertichetti M, Calza S, Agosti E, Aliaga Arias 318 319 JM, Assietti R, Bellocchi S, Bernucci C, Bistazzoni S, Bongetta D, Fanti A, Fioravanti A, Fiorindi 320 A, Franzin A, Locatelli D, Pugliese R, Roca E, Sicuri GM, Stefini R, Venturini M, Vivaldi O, 321 Zattra C, Zoia C, Fontanella MM. 2020a. Anxiety in neurosurgical patients undergoing nonurgent 322 surgery during the COVID-19 pandemic. Neurosurg Focus **49**:E19. 323 doi:10.3171/2020.9.FOCUS20681
- Doglietto F, Vezzoli M, Gheza F, Lussardi GL, Domenicucci M, Vecchiarelli L, Zanin L, Saraceno G,
   Signorini L, Panciani PP, Castelli F, Maroldi R, Rasulo FA, Benvenuti MR, Portolani N,
   Bonardelli S, Milano G, Casiraghi A, Calza S, Fontanella MM. 2020b. Factors Associated With
   Surgical Mortality and Complications Among Patients With and Without Coronavirus Disease
   2019 (COVID-19) in Italy. *JAMA Surg.* doi:10.1001/jamasurg.2020.2713
- Friedman JH. 2001. Greedy function approximation: A gradient boosting machine. Ann Stat 29:1189–
   1232. doi:10.1214/aos/1013203451

- Garrafa E, Brugnoni D, Barbaro M, Andreoli L, Focà E, Salvetti M, Castelli F, Franceschini F, Piva S,
   Muiesan ML, Latronico N, Levaggi R. 2020a. Laboratory considerations amidst the coronavirus
   disease 2019 outbreak: the Spedali Civili in Brescia experience. *Bioanalysis* 12:1223–1230.
   doi:10.4155/bio-2020-0109
- Garrafa E, Levaggi R, Miniaci R, Paolillo C. 2020b. When fear backfires: Emergency department
  accesses during the Covid-19 pandemic. *Health Policy Amst Neth* 124:1333–1339.
  doi:10.1016/j.healthpol.2020.10.006
- Gidari A, Socio GVD, Sabbatini S, Francisci D. 2020. Predictive value of National Early Warning Score
   2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. *Infect Dis* 52:698–704. doi:10.1080/23744235.2020.1784457
- Hong S, Lynn HS. 2020. Accuracy of random-forest-based imputation of missing data in the presence of
   non-normality, non-linearity, and interaction. *BMC Med Res Methodol* 20:199.
   doi:10.1186/s12874-020-01080-1
- Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, Karakike E,
  Saridaki M, Loli G, Stefos A, Prasianaki D, Georgiadou S, Tsachouridou O, Petrakis V, Tsiakos
  K, Kosmidou M, Lygoura V, Dareioti M, Milionis H, Papanikolaou IC, Akinosoglou K, Myrodia
  D-M, Gravvani A, Stamou A, Gkavogianni T, Katrini K, Marantos T, Trontzas IP, Syrigos K,
  Chatzis L, Chatzis S, Vechlidis N, Avgoustou C, Chalvatzis S, Kyprianou M, van der Meer JW,
  Eugen-Olsen J, Netea MG, Giamarellos-Bourboulis EJ. 2021. An open label trial of anakinra to
  prevent respiratory failure in COVID-19. *eLife* 10. doi:10.7554/eLife.66125
- 351 Lazar Neto F, Marino LO, Torres A, Cilloniz C, Meirelles Marchini JF, Garcia de Alencar JC, Palomeque 352 A, Albacar N, Brandão Neto RA, Souza HP, Ranzani OT, Bortolotto AL, Müller Veiga AD, 353 Bellintani AP, Fantinatti BL, Nicolao BR, Caldeira BT, Umehara Juck CE, Bueno CG, Takamune DJ, Guidotte DV, D'Souza EA, Oliveira Silva EC, Brito Miyaguchi ET, Gomes da Silva EM, 354 355 Santos Moreira EL, Fonseca e Silva FM, de Paula Maroni Escudeiro G, Travessini G, Costa GB, 356 Tibucheski dos Santos H, Omori IH, Baptista JM, Afonso Nascimento JP, de Góes Campos L, 357 Lima LT, Boscolo L, Adsuara Pandolfi MC, de Oliveira Silva M, Sanches MP, Saad Menezes 358 MC, Goncalves Cimatti De Calasans MM, Lima de Faria MF, Bezerra Martins NA, Albuquerque 359 de Moura P, Araújo Simões PA, Luna RB, Nishiaka RK, Miléo RC, de Souza Abreu R, Toccoli 360 RW, Monsalvarga TC, Brito Medeiros VM, Filippo Fernandes YS, Simões AL, Tavares AA, 361 Carvalho de Alves Pereira C, Ribeiro DR, Dias de Francesco D, Emerenciano DL, Pires de Campos EM, Moreira FL, Bortoleto FM, Martinez G, Wiebelling da Silva G, Martins GB, Leite 362 363 Fortes JC, Dias Barreto LG, Silva de Rosa ML, Ursoline do Nascimento M, Pisciolaro RF, Xavier 364 RA, Barbosa de Souza SF, Lisboa Netto TA, Ribeiro S, Faria C, Rahhal H, Padrão E, Valente F, 365 Padovan Chio YH, Gomez Gomez LM. 2021. Community-acquired pneumonia severity 366 assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. Clin Microbiol Infect. doi:10.1016/j.cmi.2021.03.002 367
- Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, Andreoli L, Franceschini F.
   2021. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral
   infection and the coagulation system. *Blood Rev* 46:100745. doi:10.1016/j.blre.2020.100745

- Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, Xu Y, Chen G, Guo H,
  Guo J, Chen Z, Zhao Y, Li S, Zhang N, Zhong N, He J, for the China Medical Treatment Expert
  Group for COVID-19. 2020. Development and Validation of a Clinical Risk Score to Predict the
  Occurrence of Critical Illness in Hospitalized Patients With COVID-19. *JAMA Intern Med*180:1081. doi:10.1001/jamainternmed.2020.2033
- Linssen J, Ermens A, Berrevoets M, Seghezzi M, Previtali G, van der Sar-van der Brugge S, Russcher
  H, Verbon A, Gillis J, Riedl J, de Jongh E, Saker J, Münster M, Munnix IC, Dofferhof A,
  Scharnhorst V, Ammerlaan H, Deiteren K, Bakker SJ, Van Pelt LJ, Kluiters-de Hingh Y, Leers
  MP, van der Ven AJ. 2020. A novel haemocytometric COVID-19 prognostic score developed
  and validated in an observational multicentre European hospital-based study. *eLife* 9:e63195.
  doi:10.7554/eLife.63195
- Lippi G, Henry BM, Hoehn J, Benoit S, Benoit J. 2020. Validation of the Corona-Score for rapid
   identification of SARS-CoV-2 infections in patients seeking emergency department care in the
   United States. *Clin Chem Lab Med CCLM* 58:e311–e313. doi:10.1515/cclm-2020-1121
- Marengoni A, Zucchelli A, Vetrano DL, Armellini A, Botteri E, Nicosia F, Romanelli G, Beindorf EA,
  Giansiracusa P, Garrafa E, Ferrucci L, Fratiglioni L, Bernabei R, Onder G. 2021. Beyond
  Chronological Age: Frailty and Multimorbidity Predict In-Hospital Mortality in Patients With
  Coronavirus Disease 2019. *J Gerontol Ser A* 76:e38–e45. doi:10.1093/gerona/glaa291
- Maroldi R, Rondi P, Agazzi GM, Ravanelli M, Borghesi A, Farina D. 2020. Which role for chest x-ray
   score in predicting the outcome in COVID-19 pneumonia? *Eur Radiol*. doi:10.1007/s00330-020 07504-2
- Martens RJH, Adrichem AJ van, Mattheij NJA, Brouwer CG, Twist DJL van, Broerse JJCR, MagroCheca C, Dongen CMP van, Mostard RLM, Ramiro S, Landewé RBM, Leers MPG. 2021.
  Hemocytometric characteristics of COVID-19 patients with and without cytokine storm
  syndrome on the sysmex XN-10 hematology analyzer. *Clin Chem Lab Med CCLM* 59:783–793.
  doi:10.1515/cclm-2020-1529
- Marziano M, Tonello S, Cantù E, Abate G, Vezzoli M, Rungratanawanich W, Serpelloni M, Lopomo
   NF, Memo M, Sardini E, Uberti D. 2019. Monitoring Caco-2 to enterocyte-like cells
   differentiation by means of electric impedance analysis on printed sensors. *Biochim Biophys Acta Gen Subj* 1863:893–902. doi:10.1016/j.bbagen.2019.02.008
- 401 Myrstad M, Ihle-Hansen H, Tveita AA, Andersen EL, Nygård S, Tveit A, Berge T. 2020. National Early
  402 Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from
  403 Covid-19 a prospective cohort study. *Scand J Trauma Resusc Emerg Med* 28:66.
  404 doi:10.1186/s13049-020-00764-3
- Salvi A, Vezzoli M, Busatto S, Paolini L, Faranda T, Abeni E, Caracausi M, Antonaros F, Piovesan A,
  Locatelli C, Cocchi G, Alvisi G, De Petro G, Ricotta D, Bergese P, Radeghieri A. 2019. Erratum:
  Analysis of a nanoparticle enriched fraction of plasma reveals miRNA candidates for down
  syndrome pathogenesis(Int J Mol Med (2019) 43(2303 2318) DOI: 10.3892/ijmm.2019.4158). *Int J Mol Med* 44:768. doi:10.3892/ijmm.2019.4222

- Schalekamp S, Huisman M, van Dijk RA, Boomsma MF, Freire Jorge PJ, de Boer WS,
  Herder GJM, Bonarius M, Groot OA, Jong E, Schreuder A, Schaefer-Prokop CM. 2020. Modelbased Prediction of Critical Illness in Hospitalized Patients with COVID-19. *Radiology*298:E46–E54. doi:10.1148/radiol.2020202723
- 414 Sperrin M, Grant SW, Peek N. 2020. Prediction models for diagnosis and prognosis in Covid-19. *BMJ* 415 369:m1464. doi:10.1136/bmj.m1464
- 416 Vezzoli M. 2011. Exploring the facets of overall job satisfaction through a novel ensemble learning.
   417 *Electron J Appl Stat Anal* 4:23-38–38. doi:10.1285/i20705948v4n1p23
- Vezzoli M, Ravaggi A, Zanotti L, Miscioscia RA, Bignotti E, Ragnoli M, Gambino A, Ruggeri G, Calza
  S, Sartori E, Odicino F. 2017. RERT: A Novel Regression Tree Approach to Predict Extrauterine
  Disease in Endometrial Carcinoma Patients. *Sci Rep* 7:10528. doi:10.1038/s41598-017-11104-4
- Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A, Starr N, Buckel W, Grisel N, Hummel E,
  Snow G, Morris D, Stenehjem E, Srivastava R, Brown SM. 2020. Clinical criteria for COVID19-associated hyperinflammatory syndrome: a cohort study. *Lancet Rheumatol* 2:e754–e763.
  doi:10.1016/S2665-9913(20)30343-X
- 425 Wynants L, Calster BV, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Dahly DL, Damen 426 JA, Debray TPA, Jong VMT de, Vos MD, Dhiman P, Haller MC, Harhay MO, Henckaerts L, 427 Heus P, Kammer M, Kreuzberger N, Lohmann A, Luijken K, Ma J, Martin GP, McLernon DJ, 428 Navarro CLA, Reitsma JB, Sergeant JC, Shi C, Skoetz N, Smits LJM, Snell KIE, Sperrin M, 429 Spijker R, Steverberg EW, Takada T, Tzoulaki I, Kuijk SMJ van, Bussel BCT van, Horst ICC 430 van der, Royen FS van, Verbakel JY, Wallisch C, Wilkinson J, Wolff R, Hooft L, Moons KGM, 431 Smeden M van. 2020. Prediction models for diagnosis and prognosis of covid-19: systematic 432 review and critical appraisal. BMJ 369:m1328. doi:10.1136/bmj.m1328
- Yavuz BG, Colak S, Guven R, Altundag İ, Seyhan AU, Inanc RG. 2021. Clinical Features of the 60
  Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality
  Earlier? *Gerontology* 1–8. doi:10.1159/000514481
- 436

# Tables

**Table 1:** Descriptive statistics on all variables in the dataset stratified respect Alive-Dead. Comparison between first (March-<br/>April) and second (May-December) wave.

	First wave: Marcl	h-April (MA) 2020		Second wave: May-Dee	cember (MD) 2020	
Variables	Alive (N=1683)	Dead (N=423)	p-value	Alive (N=594)	Dead (N=82)	p value
Age	, ř	<b>x k</b>	< 0.001*			< 0.001*
Mean (SD)	64.55 (14.27)	76.21 (9.12)		65.30 (15.20)	76.72 (10.79)	
Median	65.00	77.00		67.00	80.00	
(Q1, Q3)	(55.00, 75.00)	(72.00, 82.00)		(55.00, 77.00)	(72.25, 84.75)	
Range	19.00 - 97.00	44.00 - 98.00		18.00 - 97.00	44.00 - 98.00	
Sex			0.036**			0.131**
F	613 (36.4%)	131 (31.0%)		240 (40.4%)	26 (31.7%)	
М	1070 (63.6%)	292 (69.0%)		354 (59.6%)	56 (68.3%)	
Days in			< 0.001*			0.008*
hospital						
N-Miss	1	0		95	0	
Mean (SD)	14.15 (11.66)	11.33 (10.98)		14.95 (11.67)	17.77 (10.75)	
Median	11.00	8.00		12.00	17.50	
(Q1, Q3)	(7.00, 18.00)	(4.00, 15.00)		(7.00, 20.00)	(9.00, 25.00)	
Range	0.00 - 140.00	0.00 - 88.00		0.00 - 79.00	2.00 - 46.00	
Score			< 0.001*			< 0.001*
Mean (SD)	6.92 (4.40)	8.77 (4.39)		5.65 (4.48)	8.23 (4.63)	
Median	7.00	9.00		5.00	9.00	
(Q1, Q3)	(3.00, 10.00)	(6.00, 12.00)		(2.00, 9.00)	(5.25, 11.00)	
Range	0.00 - 18.00	0.00 - 18.00		0.00 - 18.00	0.00 - 17.00	
D-dimer			< 0.001*			< 0.001*
N-Miss	406	113		128	16	
Mean (SD)	1155.03	3124.25		1538.17 (3123.38)	4712.44	
	(2218.51)	(8070.21)			(8897.82)	
Median	443.00	944.50		739.50	1112.00	
(Q1, Q3)	(262.00, 985.00)	(476.50, 2970.75)		(427.50, 1341.25)	(725.50, 3619.25)	
Range	200.00 -	200.00 -		190.00 - 33501.00	190.00 -	
	47228.00	60342.00			35000.00	
Fibrinogen			0.951*			0.778*

First wave: March-April (MA) 2020			Second wave: May-De	cember (MD) 2020		
Variables	Alive (N=1683)	Dead (N=423)	p-value	Alive (N=594)	Dead (N=82)	p value
N-Miss	339	117		54	8	
Mean (SD)	530.53 (194.13)	530.55 (213.69)		523.94 (169.43)	519.77 (213.05)	
Median	520.00	515.00		512.00	510.00	
(Q1, Q3)	(381.00, 650.00)	(381.00, 654.00)		(405.00, 612.00)	(330.50, 649.00)	
Range	119.00 - 1339.00	68.00 - 1333.00		147.00 - 1371.00	153.00 - 1287.00	
LDH			< 0.001*			< 0.001*
N-Miss	188	92		61	7	
Mean (SD)	321.25 (227.50)	433.71 (205.10)		308.30 (196.23)	443.49 (707.95)	
Median	283.00	406.00		273.00	332.00	
(Q1, Q3)	(222.00, 373.00)	(269.50, 545.50)		(218.00, 354.00)	(257.00, 442.50)	
Range	90.00 - 6689.00	123.00 - 1365.00		108.00 - 2565.00	122.00 - 6310.00	
Neutrophils			< 0.001*			< 0.001*
N-Miss	23	19		4	1	
Mean (SD)	5.67 (3.61)	7.17 (4.39)		5.80 (3.97)	7.21 (4.13)	
Median	4.83	6.20		4.78	6.72	
(Q1, Q3)	(3.29, 7.03)	(4.12, 9.02)		(3.42, 7.11)	(4.00, 9.77)	
Range	0.00 - 53.99	0.17 - 30.45		0.10 - 47.03	0.19 - 23.02	
Lymphocytes			< 0.001*			< 0.001*
N-Miss	23	19		4	1	
Mean (SD)	1.43 (5.48)	1.19 (4.29)		1.22 (0.81)	1.38 (4.63)	
Median	1.04	0.81		1.06	0.74	
(Q1, Q3)	(0.75, 1.42)	(0.55, 1.18)		(0.72, 1.52)	(0.47, 1.06)	
Range	0.10 - 177.63	0.04 - 85.51		0.08 - 10.28	0.08 - 42.20	
Neutrophils on			<i>&lt; 0.001</i> *			< 0.001*
Lymphocytes						
N-Miss	23	19		4	1	
Mean (SD)	6.18 (5.87)	10.72 (11.71)		7.19 (9.92)	12.84 (13.09)	
Median	4.52	7.13		4.32	8.50	
(Q1, Q3)	(2.84, 7.50)	(4.47, 13.06)		(2.63, 8.40)	(4.05, 15.19)	
Range	0.00 - 101.90	0.01 - 129.67		0.12 - 143.25	0.11 - 70.56	
Neutrophils $\overline{\%}$			< 0.001*			< 0.001*
N-Miss	22	19		4	1	
Mean (SD)	0.73 (0.13)	0.80 (0.12)		0.73 (0.13)	0.79 (0.16)	
Median	0.74	0.82		0.73	0.83	

	First wave: March	n-April (MA) 2020		Second wave: May-De	cember (MD) 2020	
Variables	Alive	Dead	n-valuo	Alivo (N-594)	Dead (N-82)	n valuo
variables	(N=1683)	(N=423)	p-value	Aive (N=574)	Deau (N=02)	p value
(Q1, Q3)	(0.66, 0.82)	(0.75, 0.88)		(0.64, 0.83)	(0.69, 0.89)	
Range	0.00 - 0.97	0.01 - 0.97		0.10 - 0.99	0.10 - 0.96	
Lymphocytes			< 0.001*			< 0.001*
%						
N-Miss	22	19		4	1	
Mean (SD)	0.18 (0.11)	0.13 (0.09)		0.18 (0.11)	0.13 (0.13)	
Median	0.16	0.11		0.17	0.10	
(Q1, Q3)	(0.11, 0.23)	(0.07, 0.17)		(0.10, 0.25)	(0.06, 0.18)	
Range	0.01 - 0.97	0.01 - 0.99		0.01 - 0.88	0.01 - 0.88	
PCR			< 0.001*			0.004*
N-Miss	47	12		21	0	
Mean (SD)	77.25 (75.76)	117.68 (95.97)		64.28 (73.38)	98.59 (102.49)	
Median	55.65	99.20		39.10	74.80	
(Q1, Q3)	(17.30, 111.60)	(42.80, 170.45)		(12.30, 91.10)	(20.12, 140.73)	
Range	0.30 - 479.00	0.70 - 471.10		0.30 - 483.20	0.30 - 593.80	
WBC			< 0.001*			0.011*
N-Miss	21	19		4	1	
Mean (SD)	7.73 (7.13)	9.13 (7.46)		7.65 (4.17)	9.23 (6.25)	
Median	6.62	7.62		6.67	8.34	
(Q1, Q3)	(4.87, 9.11)	(5.60, 10.74)		(5.02, 8.90)	(5.55, 12.04)	
Range	0.72 - 191.02	0.32 - 92.23		0.97 - 48.19	0.97 - 47.79	
Basophils			0.073*			0.419*
N-Miss	23	19		4	1	
Mean (SD)	0.02 (0.02)	0.02 (0.02)		0.02 (0.04)	0.02 (0.02)	
Median	0.01	0.01		0.02	0.01	
(Q1, Q3)	(0.01, 0.02)	(0.01, 0.02)		(0.01, 0.03)	(0.01, 0.03)	
Range	0.00 - 0.31	0.00 - 0.15		0.00 - 0.84	0.00 - 0.11	
Basophils %			< 0.001*			0.024*
N-Miss	22	19		4	1	
Mean (SD)	0.00 (0.00)	0.00 (0.00)		0.00 (0.00)	0.00 (0.00)	
Median	0.00	0.00		0.00	0.00	
(Q1, Q3)	(0.00, 0.00)	(0.00, 0.00)		(0.00, 0.00)	(0.00, 0.00)	
Range	0.00 - 0.02	0.00 - 0.06		0.00 - 0.05	0.00 - 0.01	
Eosinophils			< 0.001*			0.015*

	First wave: Marcl	h-April (MA) 2020		Second wave: May-De	cember (MD) 2020	
Variables	Alive (N=1683)	Dead (N=423)	p-value	Alive (N=594)	Dead (N=82)	p value
N-Miss	23	19		4	1	
Mean (SD)	0.06 (0.12)	0.04 (0.10)		0.06 (0.14)	0.05 (0.13)	
Median	0.01 (0.00, 0.07)	0.00 (0.00, 0.02)		0.01 (0.00, 0.06)	0.00 (0.00, 0.03)	
(Q1, Q3)						
Range	0.00 - 2.19	0.00 - 0.79		0.00 - 1.95	0.00 - 0.97	
Eosinophils %			< 0.001*			0.013*
N-Miss	22	19		4	1	
Mean (SD)	0.01 (0.02)	0.00 (0.01)		0.01 (0.02)	0.01 (0.01)	
Median	0.00	0.00		0.00	0.00	
(Q1, Q3)	(0.00, 0.01)	(0.00, 0.00)		(0.00, 0.01)	(0.00, 0.00)	
Range	0.00 - 0.27	0.00 - 0.12		0.00 - 0.25	0.00 - 0.07	
Monocytes			< 0.001*			0.683*
N-Miss	23	19		4	1	
Mean (SD)	0.56 (0.68)	0.69 (3.32)		0.55 (0.32)	0.58 (0.41)	
Median	0.47	0.41		0.49	0.48	
(Q1, Q3)	(0.32, 0.68)	(0.25, 0.63)		(0.33, 0.68)	(0.27, 0.77)	
Range	0.01 - 23.31	0.02 - 66.34		0.02 - 2.45	0.07 - 2.01	
Monocytes %			< 0.001*			0.034*
N-Miss	22	19		4	1	
Mean (SD)	0.08 (0.04)	0.07 (0.05)		0.08 (0.04)	0.07 (0.05)	
Median	0.07 (0.05, 0.10)	0.06 (0.04, 0.08)		0.07 (0.05, 0.10)	0.06 (0.04, 0.09)	
(Q1, Q3)						
Range	0.00 - 0.70	0.01 - 0.72		0.01 - 0.31	0.01 - 0.27	p value
Ferritin F	613 patients	131 patients		240 patients	26 patients	0.372*
	(82.39%)	(17.61%)	<i>&lt; 0.001</i> *	(90.23%)	(9.77%)	
N-Miss	158	34		43	5	
Mean (SD)	674.53 (817.61)	1237.07		564.63 (526.39)	2006.00	
		(2308.64)			(4680.23)	
Median	459.00	700.00		433.00	510.00	
(Q1, Q3)	(212.00, 820.50)	(353.00, 1347.00)		(216.00, 750.00)	(269.00, 722.00)	
Range	4.00 - 7687.00	19.00 - 20572.00		11.00 - 3397.00	81.00 - 20941.00	
Ferritin M	1070 patients	292 patients	< 0.001*	354 patients	56 patients	0.007*
	(78.56%)	(21.44%)		(90.23%)	(9.77%)	
N-Miss	257	96		50	5	

	First wave: March-April (MA) 2020		Second wave: May-Dec			
Variables	Alive (N=1683)	Dead (N=423)	p-value	Alive (N=594)	Dead (N=82)	p value
Mean (SD)	1353.00	1825.25		1181.95 (3295.92)	1372.04	
	(1359.86)	(1945.47)			(1258.14)	
Median	939.00	1262.50		737.50	1159.00	
(Q1, Q3)	(461.00, 1705.00)	(572.25, 2323.25)		(405.25, 1283.00)	(598.00, 1500.00)	
Range	23.00 - 11513.00	55.00 - 13289.00		25.00 - 56039.00	112.00 - 7058.00	

In bold and italics p-values<0.05 \* Wilcoxon rank-sum test t

\*\* Fisher's exact test

Table 2: Performance metrics of methods: Random Forest, Gradient Boosting Machine (GBM) and Logistic Regression

	R	Random Fores	st		GBM		LOGISTIC REGRESSION		
Metrics	Training March- April (MA)	Validating March- April (MA)	Testing May-Dec (MD)	Training March- April (MA)	Validating March- April (MA)	Testing May-Dec (MD)	Training March- April (MA)	Validating March- April (MA)	Testing May-Dec (MD)
AUC (DeLong) (95% CI)	0.97 (0.97-0.98)	0.83 (0.80-0.87)	0.78 (0.73-0.84)	0.88 (0.86-0.89)	0.84 (0.80-0.88)	0.78 (0.73-0.83)	0.84 (0.82-0.86)	0.83 (0.79-0.87)	0.52 (0.44-0.60)
Sensitivity	0.93	0.82	0.73	0.85	0.80	0.77	0.80	0.84	0.87
(95% CI)	(0.91 - 0.97)	(0.72 - 0.92)	(0.54 - 1.00)	(0.80 - 0.88)	(0.66-0.90)	(0.65-0.94)	(0.77 - 0.84)	(0.76-0.91)	(0.18 - 1.00)
Specificity	0.92	0.75	0.73	0.77	0.75	0.71	0.74	0.73	0.26
(95% CI)	(0.88-0.94)	(0.63-0.83)	(0.41 - 0.89)	(0.73-0.81)	(0.65-0.87)	(0.50-0.79)	(0.70 -0.77)	(0.65-0.79)	(0.11-0.94)

Comparison between the performances of three methods: Random Forest, GBM and Logistic Regression model applied on the rebalanced dataset obtained with SMOTE methodology. Logistic Regression predictions are computed using the 10-fold cross-validation in order to be comparable with Random Forest and GBM predictions (which use out-of-bag and 10-fold cross-validation, respectively).

### **Figures**

Figure 1: Flow-chart of the data used in the empirical analyses



The BS-EWM was trained with a Random Forest on 70% of first wave patients (rebalanced with the SMOTE procedure) and (*i*) validated on remaining 30% of first wave patients (*ii*) tested on 676 second wave patients. In detail, 2106 patients were randomly in training and validating, maintaining the same death prevalence of the first wave.

Figure 2: Relative Variable importance Measure (rel VIM) and PDP



**PANEL A**: Relative Variable importance Measure (rel VIM) extracted from the Random Forest considering "Age" (A1) or excluding "Age" (A2).

**Panel B**: Partial Dependence Plot (PDP) in correspondence of variables with VIM>60 (cut-off identified by the red dashed line) extracted from Random Forest without "Age" (A2) and p-value in Table 1 <0.05. PDPs are displayed from the most to the less important variable.



#### Figure 3: ROC curves of Random Forest, GBM and Logistic Regression

ROC curves of three methods: (*i*) Random Forest, (*ii*) GBM and (*iii*) Logistic Regression. Each graph reports the ROC curve computed in Training (blue line, 70% of March-April's patients) Validating (dashed red line, 30% of March-April's patients), and Testing (dashed green lined, May-December patients).

# **Supplementary Tables**

Table S.1: Descriptive statistics on all variables of the entire sample

Variables	Overall (N=2782)
Age	
Mean (SD)	66.84 (14.44)
Median (Q1, Q3)	69.00 (57.00, 78.00)
Range	18.00 - 98.00
Sex	
F	1010 (36.3%)
M	1772 (63.7%)
Days in hospital	
N-Miss	96
Mean (SD)	13.96 (11.60)
Median $(01, 03)$	11.00 (6.00, 18.00)
Range	0.00 - 140.00
Score	0.00 - 140.00
Moon (SD)	6 07 (4 52)
Median (O1 O2)	7.00(2.00, 10.00)
Median $(Q1, Q3)$	7.00 (3.00, 10.00)
Kange	0.00 - 18.00
D-dimer	
IN-MISS	663
Mean (SD)	1638.18 (4218.89)
Median (Q1, Q3)	578.00 (315.50, 1289.50)
Range	190.00 - 60342.00
Fibrinogen	
N-Miss	518
Mean (SD)	528.61 (191.92)
Median (Q1, Q3)	515.00 (391.00, 637.00)
Range	68.00 - 1371.00
LDH	
N-Miss	348
Mean (SD)	337.48 (251.21)
Median (Q1, Q3)	291.50 (226.00, 395.00)
Range	90.00 - 6689.00
Neutrophils	
N-Miss	47
Mean (SD)	5 96 (3 87)
Median $(01, 03)$	503(343,748)
Range	0.00 - 53.99
I vmnhoevtes	0.00 55.55
N-Miss	17
$\frac{1}{1000}$	1 35 (4 66)
Median $(O1, O3)$	1.00 (0.60 1.40)
$\frac{1}{2} \sum_{i=1}^{n} \frac{1}{2} \sum_{i=1}^{n} \frac{1}$	1.00(0.09, 1.40) 0.04 - 177.62
Nanta and its and the second second	0.04 - 177.03
N Mine	47
IN-IVIISS	4/
$\frac{1}{100} \frac{1}{100} \frac{1}$	1.27 (8.41)
Median (Q1, Q3)	4.89 (2.96, 8.69)
Kange	0.00 - 143.25
Neutrophils %	
N-Miss	46
Mean (SD)	0.74 (0.13)
Median (Q1, Q3)	0.76 (0.67, 0.84)
Range	0.00 - 0.99
Lymphocytes %	
N-Miss	46
Mean (SD)	0.17 (0.11)
Mean (SD) Median (Q1, Q3)	0.17 (0.11) 0.16 (0.10, 0.23)

Variables	Overall (N=2782)			
PCR				
N-Miss	80			
Mean (SD)	81.30 (81.30)			
Median (Q1, Q3)	56.70 (18.20, 117.55)			
Range	0.30 - 593.80			
WBC				
N-Miss	45			
Mean (SD)	7.97 (6.65)			
Median (Q1, Q3)	6.82 (5.00, 9.40)			
Range	0.32 - 191.02			
Basophils				
N-Miss	47			
Mean (SD)	0.02 (0.03)			
Median (Q1, Q3)	0.01 (0.01, 0.03)			
Range	0.00 - 0.84			
Basophils %				
N-Miss	46			
Mean (SD)	0.00 (0.00)			
Median (Q1, Q3)	0.00 (0.00, 0.00)			
Range	0.00 - 0.06			
Eosinophils				
N-Miss	47			
Mean (SD)	0.05 (0.12)			
Median (Q1, Q3)	0.01 (0.00, 0.06)			
Range	0.00 - 2.19			
Eosinophils %				
N-Miss	46			
Mean (SD)	0.01 (0.02)			
Median (Q1, Q3)	0.00 (0.00, 0.01)			
Range	0.00 - 0.27			
Monocytes				
N-Miss	47			
Mean (SD)	0.58 (1.39)			
Median (Q1, Q3)	0.47 (0.31, 0.68)			
Range	0.01 - 66.34			
Monocytes %				
N-M1ss	46			
Mean (SD)	0.08 (0.04)			
Median (Q1, Q3)	0.07 (0.05, 0.10)			
Range	0.00 - 0.72			

	Al	ive	_	Dead		_
Variables	March-April (MA) (N=1683)	May- December (MD) (N=594)	p-value	March-April (MA) (N=423)	May- December (MD) (N=82)	p value
Age			0.1503*			0.2041*
Mean (SD)	64.55 (14.27)	65.30 (15.20)		76.21 (9.12)	76.72 (10.79)	
Median	65.00	67.00		77.00	80.00	
(Q1, Q3)	(55.00, 75.00)	(55.00, 77.00)		(72.00, 82.00)	(72.25, 84.75)	
Range	19.00 - 97.00	18.00 - 97.00		44.00 - 98.00	44.00 - 98.00	
Sex			0.0936**			0.8968**
F	613 (36.4%)	240 (40.4%)		131 (31.0%)	26 (31.7%)	
Μ	1070 (63.6%)	354 (59.6%)		292 (69.0%)	56 (68.3%)	
Days in			0.2122*			< 0.001*
hospital						
N-Miss	1	95		0	0	
Mean (SD)	14.15 (11.66)	14.95 (11.67)		11.33 (10.98)	17.77 (10.75)	
Median	11.00	12.00		8.00	17.50	
(Q1, Q3)	(7.00, 18.00)	(7.00, 20.00)		(4.00, 15.00)	(9.00, 25.00)	
Range	0.00 - 140.00	0.00 - 79.00		0.00 - 88.00	2.00 - 46.00	
Score			< 0.001*			0.3965*
Mean (SD)	6.92 (4.40)	5.65 (4.48)		8.77 (4.39)	8.23 (4.63)	
Median	7.00	5.00		9.00	9.00	
(Q1,Q3)	(3.00, 10.00)	(2.00, 9.00)		(6.00, 12.00)	(5.25, 11.00)	
Range	0.00 - 18.00	0.00 - 18.00		0.00 - 18.00	0.00 - 17.00	
D-dimer			< 0.001*			0.0452*
N-Miss	406	128		113	16	
Mean (SD)	1155.03	1538.17		3124.25 (8070.21)	4712.44	
	(2218.51)	(3123.38)			(8897.82)	
Median	443.00	739.50		944.50	1112.00	
(01, 03)	(262.00.	(427.50.		(476.50, 2970.75)	(725.50.	
	985.00)	1341.25)		()	3619.25)	
Range	200.00 -	190.00 -		200.00 - 60342.00	190.00 -	
8-	47228.00	33501.00			35000.00	
Fibrinogen			0.7502*			0.6711*
N-Miss	339	54	011002	117	8	010711
Mean (SD)	530.53	523.94		530.55 (213.69)	519.77	
(52)	(194.13)	(169.43)			(213.05)	
Median	520.00	512.00		515.00	510.00	
(01, 03)	(381.00.	(405.00.		(381.00, 654.00)	(330.50.	
$(\mathbf{x}^{1}, \mathbf{x}^{2})$	650.00)	612.00)		(001100,001100)	649.00)	
Range	119.00 -	147.00 -		68.00 - 1333.00	153.00 -	
Tunge	1339.00	1371.00			1287.00	
LDH	1223100	10/1100	0.0298*		1207.00	0.0094*
N-Miss	188	61	0.0270	92	7	
Mean (SD)	321.25	308 30		433 71 (205 10)	443 49	
(52)	(227.50)	(196.23)		(200110)	(707.95)	
Median	283.00	273.00		406.00	332.00	
(01, 03)	(222.00	(218.00		(269 50 545 50)	(257.00	
$(\mathbf{q}^{1},\mathbf{q}^{2})$	373.00)	354.00)		(20)100, 010100)	442 50)	
Range	90.00 -	108.00 -		123.00 - 1365.00	122.00 -	
Runge	6689.00	2565.00		125.00 1505.00	6310.00	
Neutronhils	0007.00	2303.00	0 8529*		0010.00	0.6350*
N-Miss	23	4	0.0527	19	1	0.0550
Mean (SD)	5 67 (3 61)	5 80 (3 97)		7 17 (4 39)	7 21 (4 13)	
Median	4 83	4 78		6 20	672	
$(01 \ 03)$	(3.29, 7, 03)	(3.42, 7.11)		(4.12, 9.02)	(4.00 9 77)	
Range	0.00 - 53.99	0.10 - 47.03		0 17 - 30 45	0.19 - 23.02	
ivange	0.00 - 55.79	0.10 77.03		0.17 50.45	0.17 23.02	

**Table S.2:** Descriptive statistics on all variables in the dataset stratified respect first (March-April 2020) and second (May-December 2020) wave. Comparison between Alive and Dead.

	Al	ive		Dead		
Variables	March-April (MA) (N=1683)	May- December (MD) (N=594)	p-value	March-April (MA) (N=423)	May- December (MD) (N=82)	p value
Lymphocytes			0.6287*			0.2115*
N-Miss	23	4		19	1	
Mean (SD)	1.43 (5.48)	1.22 (0.81)		1.19 (4.29)	1.38 (4.63)	
Median	1.04	1.06		0.81	0.74	
(Q1,Q3)	(0.75, 1.42)	(0.72, 1.52)		(0.55, 1.18)	(0.47, 1.06)	
Range	0.10 - 177.63	0.08 - 10.28		0.04 - 85.51	0.08 - 42.20	
Neutrophils			0.8639*			0.3122*
on						
Lymphocytes						
N-Miss	23	4		19	1	
Mean (SD)	6.18 (5.87)	7.19 (9.92)		10.72 (11.71)	12.84 (13.09)	
Median	4.52	4.32		7.13	8.50	
(Q1, Q3)	(2.84, 7.50)	(2.63, 8.40)		(4.47, 13.06)	(4.05, 15.19)	
Range	0.00 - 101.90	0.12 - 143.25		0.01 - 129.67	0.11 - 70.56	
Neutrophils			0.6134*			0.6882*
%				10		
N-M1ss	22	4		19		
Mean (SD)	0.73 (0.13)	0.73 (0.13)		0.80 (0.12)	0.79 (0.16)	
Median	0.74	0.73		0.82	0.83	
(Q1,Q3)	(0.66, 0.82)	(0.64, 0.83)		(0.75, 0.88)	(0.69, 0.89)	
Range	0.00 - 0.97	0.10 - 0.99	0.020*	0.01 - 0.97	0.10 - 0.96	0.000.1*
Lymphocytes %			0.933*			0.2924*
N-Miss	22	4		19	1	
Mean (SD)	0.18 (0.11)	0.18 (0.11)		0.13 (0.09)	0.13 (0.13)	
Median	0.16	0.17		0.11	0.10	
(Q1, Q3)	(0.11, 0.23)	(0.10, 0.25)		(0.07, 0.17)	(0.06, 0.18)	
Range	0.01 - 0.97	0.01 - 0.88		0.01 - 0.99	0.01 - 0.88	
PCR			<0.001*			0.0235*
N-Miss	47	21		12	0	
Mean (SD)	77.25 (75.76)	64.28 (73.38)		117.68 (95.97)	98.59	
		20.10		00 <b>0</b> 0	(102.49)	
Median	55.65	39.10		99.20	74.80	
(Q1, Q3)	(17.30,	(12.30, 91.10)		(42.80, 170.45)	(20.12,	
D	111.60)	0.20 492.20		0.70 471 10	140.73)	
Range	0.30 - 479.00	0.30 - 483.20	0.4606*	0./0 - 4/1.10	0.30 - 593.80	0.(100*
WBC	21	4	0.4686*	10	1	0.6138*
IN-IVIISS Maan (SD)	21 (1 1 2) 27 7	4 7 65 (4 17)		19	1	
Median	1.13 (1.13)	7.03 (4.17)		9.15 (7.40)	9.23 (0.23)	
(01, 02)	(4.87, 0.11)	(5.02.8.00)		7.02 (5.60, 10.74)	0.34 (5.55, 12.04)	
(Q1,Q3)	(4.07, 9.11) 0.72 101.02	(3.02, 8.90)		(3.00, 10.74) 0.22, 02.22	(3.33, 12.04) 0.07 47.70	
Besophile	0.72 - 191.02	0.97 - 40.19	0.0013*	0.32 - 92.23	0.97 - 47.79	0.2253*
N-Miss	23	4	0.0015	19	1	0.2255
Mean (SD)	0.02(0.02)	0.02(0.04)		0.02(0.02)	0.02(0.02)	
Median	0.02 (0.02)	0.02 (0.04)		0.02 (0.02)	0.02 (0.02)	
(01, 03)	(0.01, 0.02)	(0.01, 0.03)		(0.01, 0.02)	(0.01, 0.03)	
Range	0.00 - 0.31	0.00 - 0.84		0.01, 0.02)	0.01, 0.03)	
Basonhils %	0.00 0.01	0.00 0.04	0.0012*	0.00 0.15	0.00 0.11	0.1017*
N-Miss	22	4	0,0012	19	1	0.1017
Mean (SD)	0.00(0.00)	0 00 (0 00)		0.00 (0.00)	0.00 (0.00)	
Median	0.00	0.00		0.00	0.00	
$(01 \ 03)$	(0,00,0,00)	(0,00,0,00)		(0,00,0,00)	(0,00,0,00)	
Range	0.00 - 0.02	0.00 - 0.05		0.00 - 0.06	0.00 - 0.01	
Eosinonhils	0.00 0.02	0.00 0.05	0.4863*	0.00 0.00	0.00 0.01	0.9056*
N-Miss	23	4	0.1005	19	1	0.2020
., ., .,		•		12	*	

	Ali	ve		Dead		
Variables	March-April (MA) (N=1683)	May- December (MD) (N=594)	p-value	March-April (MA) (N=423)	May- December (MD) (N=82)	p value
Mean (SD)	0.06 (0.12)	0.06 (0.14)		0.04 (0.10)	0.05 (0.13)	
Median	0.01	0.01		0.00	0.00	
(Q1, Q3)	(0.00, 0.07)	(0.00, 0.06)		(0.00, 0.02)	(0.00, 0.03)	
Range	0.00 - 2.19	0.00 - 1.95		0.00 - 0.79	0.00 - 0.97	
Eosinophils			0.4902*			0.9885*
%						
N-Miss	22	4		19	1	
Mean (SD)	0.01 (0.02)	0.01 (0.02)		0.00 (0.01)	0.01 (0.01)	
Median	0.00	0.00		0.00	0.00	
(Q1, Q3)	(0.00, 0.01)	(0.00, 0.01)		(0.00, 0.00)	(0.00, 0.00)	
Range	0.00 - 0.27	0.00 - 0.25		0.00 - 0.12	0.00 - 0.07	
Monocytes	• •		0.253*	10		0.1643*
N-M1ss	23	4		19	1	
Mean (SD)	0.56 (0.68)	0.55 (0.32)		0.69 (3.32)	0.58 (0.41)	
Median	0.47	0.49		0.41	0.48	
(Q1,Q3)	(0.32, 0.68)	(0.33, 0.68)		(0.25, 0.63)	(0.27, 0.77)	
Range	0.01 - 23.31	0.02 - 2.45	0.001.4*	0.02 - 66.34	0.07 - 2.01	0.0654*
Monocytes			0.6814*			0.2654*
% 	22	4		10	1	
IN-IVIISS Maar (SD)	22			19		
Median	0.08 (0.04)	0.08(0.04)		0.07(0.03)	0.07(0.03)	
(01, 02)	0.07 (0.05,	0.07 (0.03,		0.00 (0.04, 0.08)	0.06 (0.04,	
(Q1, Q3)	0.10)	0.10)		0.01 0.72	0.09)	n valua
Formitin F	613 nationts	240 nationts	0.4706*	0.01 - 0.72	0.01 - 0.27	0 2085*
rerrium r	(82.39%)	(90.23%)	0.4700	(17.61%)	(9.77%)	0.3983
N-Miss	158	43		34	5	
Mean (SD)	674.53	564.63		1237.07 (2308.64)	2006.00	
	(817.61)	(526.39)			(4680.23)	
Median	459.00	433.00		700.00	510.00	
(Q1, Q3)	(212.00,	(216.00,		(353.00, 1347.00)	(269.00,	
_	820.50)	750.00)			722.00)	
Range	4.00 -	11.00 -		19.00 - 20572.00	81.00 -	
	/68/.00	3397.00	0.0074		20941.00	0.1.5.5.1
Ferritin M	1070 patients (78.56%)	354 patients (90.23%)	<0.001*	292 patients (21.44%)	56 patients (9.77%)	0.1555*
N-Miss	257	50		96	5	
Mean (SD)	1353.00	1181.95		1825.25 (1945.47)	1372.04	
	(1359.86)	(3295.92)			(1258.14)	
Median	939.00	737.50		1262.50	1159.00	
(Q1,Q3)	(461.00,	(405.25,		(572.25, 2323.25)	(598.00,	
	1705.00)	1283.00)			1500.00)	
Range	23.00 -	25.00 -		55.00 - 13289.00	112.00 -	
	11513.00	56039.00			7058.00	

In bold and italics p-values<0.05

\* Wilcoxon rank-sum test t

\*\* Fisher's exact test

**Table S.3:** Performance metrics of the Random Forest (RF) using or not a rebalanced dataset with the SMOTE methodology

	RF on a dataset ro SMOTE m	ebalanced with the ethodology	RF on the original dataset		
Metrics	TrainingValidatingMarch-April (MA)March-April (MA)(95% CI)(95% CI)		Training March-April (MA) (95% CI)	Validating March-April (MA) (95% CI)	
AUC (DeLong)	0.97-0.98	0.80-0.87	0.82-0.86	0.81-0.88	
Sensitivity	0.93 (0.91-0.97)	0.82 (0.72-0.92)	0.81 (0.76-0.85)	0.79 (0.66-0.95)	
Specificity	0.92 (0.88-0.94)	0.75 (0.63-0.83)	0.76 (0.73-0.79)	0.76 (0.57-0.86)	

In this table we compare the performance of two RFs applied on (i) a dataset rebalanced with the SMOTE methodology (ii) the original dataset. This analysis suggests the use of SMOTE methodology before applying RF since the performance in Training and Validating groups (especially in terms of sensitivity) are better respect those obtained from the RF grown on the original dataset.





The relationships between 17 analytes and Brescia chest-xray score are inspected with the Spearman correlation coefficients,  $\rho_s$  which are represented in this correlation plot by means of blue and red circles (positive and negative correlation, respectively). The diameter of the circle is proportional to the magnitude of  $\rho_s$  and black crosses on them identify correlation not significantly different from zero (p-values>0.05). The correlation matrix is reordered according to the hierarchical cluster analysis on the quantitative variables.